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measure shrinkage or progression months after a therapy is initiated. 
Also, electronic “rulers” and emerging automated lesion measure-
ment algorithms can routinely permit same-day response assessment. 
Coupling this to a web-based case report form can inform the treating 
physician, investigator, and sponsor of a treatment’s effect the same 
day. All this technology is in place at most medical centers and needs 
only to be applied.
The entire process can be improved in other ways as well. Clinical 
trials should not lose their focus on the primary study endpoint: dose 
(deﬁned by toxicity or effectiveness) for Phase I and effectiveness for 
Phase II. Despite our best efforts to use preclinical information to select 
and prioritize agents for testing in persons with lung cancer, most com-
pounds prove to be too toxic and/or ineffective to warrant further study. 
Knowing this unfortunate reality, expending resources for pharmacol-
ogy, correlative, and quality of life studies as part of phase I and Phase 
II trials carries with it a high likelihood of irrelevance when obtained 
from patients receiving sub-therapeutic doses in phase I, when the 
drug is shown to be toxic in phase I, or ineffective in phase II. These 
important efforts are appropriate once a safe dose and threshold of 
activity are achieved, i.e., when a sufﬁcient number if responses have 
been documented in the ﬁrst stage of a two-stage trial design. The more 
streamlined the trial, the more likely it will be to quickly accrue and 
answer the primary question posed. Biology-based therapies provide 
another opportunity to hasten drug development. Their testing permits 
the enrichment of the study group to include only those individuals 
whose tumors contain the pathway or molecule that is the target of the 
therapy. If an agent does not prove effective in these individuals, it 
usefulness in the general population of patients with lung cancer will be 
highly unlikely. Lastly, assessment of the primary study endpoint must 
be determined in real time. Any severe toxicity effects the enrollment 
of the very next person in phase I. Rapid documentation of response 
or progression can prevent the needless accrual of patients on studies 
of ineffective agents and delay in studies destined to continue while 
response data is collected.
There are additional points to consider for phase I studies. The goal of 
a phase I study is to determine a phase II dose. All other questions are 
secondary and irrelevant if the primary objective is not achieved. Rapid 
(one patient per level if no toxicity is seen) dose escalation can greatly 
hasten a phase I effort and it limits the number of patients receiving 
what eventually are proven to be sub-therapeutic dosages. Even in 
phase I, focusing on the patient group for whom the treatment was 
designed will speed the process. Volunteer studies do not facilitate this. 
The average age, concomitant medications, and co-morbid conditions 
of volunteers bear little resemblance to patients with lung cancer. In ad-
dition, volunteers are exposed to risk when they receive an anticancer 
therapy with no chance of beneﬁt. Studying new drugs in persons with 
cancer who have no therapy with a higher likelihood of beneﬁt avail-
able to them is a much better approach. For therapies where the target 
is known, even phase I trials beneﬁt from enriching the study group 
with individuals whose tumors bear the target.
For phase II trials, it is critical to use the most effective imaging 
techniques (in most cases a helical CT) to assess lesion size and to 
measure response after just one cycle or less to rule out progression 
and assess beneﬁt. For targeted therapies, initial enrollment should be 
restricted to individuals whose tumors have the target. Consideration 
should also be given to enrich for optimal indicator lesions that will 
allow the most rapid and accurate assessment of lesion size. Selecting 
the largest or selected indicator lesions (pulmonary lesions surrounded 
by aerated lung and hepatic metastases) can further improve accuracy 
and hasten the process. Each helical CT study contains a tremendous 
amount of information that should not be wasted. Uni- and bidimen-
sional measurements as well as volumetric and density determinations 
for each patient (waterfall plots) aid in making the decision whether or 
not an agent is “active”. Relying solely on “standard response criteria”. 
can be misleading. Using RECIST criteria, patients with 29% regres-
sions and 19% growth are both labeled “stable”! Ten percent regression 
or growth represents a true change using current CT technology. We 
have seen that any growth vs any regression is associated with overall 
survival, even in the relatively small number of patients included in 
phase II trials. At the very least, patients should be removed from study 
as soon as unequivocal growth has been documented. This strategy 
is in the best interest of the patient and the trial. The same is true for 
real time measurement. It makes no sense that an additional level of 
review and scrutiny (use of a reference radiologist) is routinely applied 
to measurements for the trial weeks or months after the same scan was 
measured and used to make therapeutic decisions. The most thorough 
review possible should be used for both clinical decisions and the study 
and immediately included in the on-line case report form. Alternative 
study designs (for example, adaptive designs) may also improve the 
efﬁciency of the process.
There has never been a better time to rethink how we identify new 
agents in the clinic. Imaging technology, information engineering, 
and statistical methodology advances are waiting to be applied to the 
clinical trials process. The result will be the more accurate and swift 
evaluation of the growing number anticancer therapies emerging from 
academic laboratories and the pharmaceutical industry. Only by ﬁnding 
new therapies can we break the barrier to cure.
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Cervical mediastinoscopy (CM) was ﬁrst reported in 1959 by Car-
lens.(1) For nearly 50 years it has been the cornerstone of minimally 
invasive mediastinal staging. CM remains today the gold standard 
technique to evaluate and stage the superior mediastinum by which 
new techniques are compared. It allows sampling of both paratracheal 
and tracheobronchial areas (stations 2R, 2L, 4R, 4L) as well as of the 
anterior subcarinal space (station 7). 
Accuracy: 
When discussing the accuracy of CM to evaluate of mediastinal nodal 
involvement (N2-3), false negative rates of 8-10% are often mentioned. 
In truth a large proportion of missed involved mediastinal nodes with 
CM are in nodal stations situated outside of the ﬁeld/ yield of CM such 
as in the periesophageal area(station 8). A series of 1745 consecutive 
staging CM from Barnes in St-Louis reported in 1999 described a 8% 
false negative rate, 12% of these had initially been called negative on 
frozen section analysis and 74% were found in nodal stations outside 
of the CM ﬁeld. (2) A more recent series of 1459 consecutive stag-
ing mediastinoscopies performed in between 1996 and 2005 at Duke, 
reported a false negative rate of 5.5% with 57% of missed involved 
lymph nodes located in stations 5,6,8,9, i.e. out of the ﬁeld of DM. (3) 
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Obviously, like with other procedures, the accuracy of CM correlates 
with the degree of “aggressiveness” one chooses to have and also on 
the experience of the operator.
Safety:
In trained hands, CM has been shown to be safe with reported mortality 
rates of less than 0.1%. The two large North American series mentioned 
above reported similar mortality rates at 0.05% and morbidity rates 
of 0.6% and 1.07% respectively. (2, 3) In the St-Louis series, half of 
the complications were post-operative dysrythmias. The incidences of 
pulmonary artery laceration, esophageal perforation and pneumothorax 
were 0.05% each. (2) In the Duke series, the following complication 
rates were listed: hemorrhage 0.33%, recurrent laryngeal nerve injury 
0.55%, tracheal injury 0.09%, pneumothorax 0.09%. Five of the seven 
bleeds occurred as a result of biopsies done in the 4R area. ( 3) Finally, 
CM was shown to be safely performed in an ambulatory surgery  
setting. (4)
Prognosis:
More than 20 years ago, pre CT and PET scan staging, Pearson and col-
leagues from Toronto suggested a certain heterogeneity of patients with 
N2 disease whether N2 was identiﬁed at CM or whether it was found 
at thoracotomy after a negative CM. In a group of surgically resected 
patients it was noted that the prognosis of patients with N2 disease 
whose N2 involvement was identiﬁed at CM but in whom a resection 
was attempted was much less than the prognosis of patients in whom 
N2 disease was identiﬁed at thoracotomy (after negative CM) and 
then resected. (5) In this same experience, it was noted that the ability 
to achieve a R0 resection was much less in patients where the CM 
had been positive. With today’s modern imaging, with such patients, 
one would hope that our ability to predict completeness of resection 
would be superior but, in the author’s experience, the ﬁnding of even 
“minimal” positive nodal disease at mediastinoscopy is often associated 
with quite advanced nodal disease at thoracotomy despite relatively 
favorable imaging. This notion of N2 disease being heterogeneous was 
further emphasized by Andre et al. who proposed a sub-classiﬁcation of 
N2 disease along the same lines. (6) 
Routine CM or not:
For many years and still today in many parts of the world, computed 
tomography scans (CT) was/ is the preferred non invasive technique 
to image and stage the mediastinum. Unfortunately, using size criteria 
alone, CT’ s performance is relatively poor with a sensitivity 57%, 
speciﬁcity of 52%, a positive predictive value (PPV) of 56% and a 
negative predictive value (NPV) of 83% as reported in a recent pooled 
analysis by Toloza and colleagues. (7) For many, these numbers are 
considered unacceptable and as such, if using CT alone to image the 
mediastinum at presentation, one should consider a routine use of 
CM in the staging of all potentially resectable patients with proven or 
suspected lung cancer.
FDG PET scanning ( and CT-PET) has been shown to be superior to 
CT in staging the mediastinum with, in some series, sensitivities and 
NPVs comparable to those of CM. As a result, it is reasonable to omit 
CM staging in patients with clinical peripheral stage I disease as as-
sessed by PET. One should be careful however in trusting FDG PET’s 
negative assessment of the mediastinum in the presence of centrally 
located cancers, of extremely FDG avid primary tumors, of primary 
tumors with little to no FDG uptake such a bronchioloalveolar carcino-
mas, in patients with clinical N1 disease and in the presence large PET 
negative mediastinal LNs. In such cases, CM should probably remain 
part of the evaluation of otherwise potentially resectable patients. The 
PPV of FDG PET is only about 80% and in such cases tissue conﬁrma-
tion of nodal involvement is always recommended for potential surgical 
candidates. (8)
Video-mediastinoscopy
CM can now be performed with a video-mediastinoscope which al-
lows improved visualization and potentially it accuracy and safety as 
well. The main advantage of video-mediastinoscopy is in teaching the 
procedure.
EBUS and EUS FNA
New endoscopic minimally invasive techniques such as EUS FNA 
and EBUS allow ultrasound guided trans”wall” aspiration and biopsy 
of mediastinal lymph nodes located in the vicinity of the esophagus 
or main airways. These techniques are newer and the initial reported 
experience using them to evaluate the possibility of mediastinal nodal 
involvement is encouraging. The NPV of these procedures is low how-
ever and negative returns should be considered inconclusive and lead 
to more invasive staging by CM. It also remains to be seen if these tests 
will be as accurate as described by the few reporting experts once their 
use becomes more generalized. Likely, these new tools will become 
complementary to CM is helping the clinicians in best assessing the 
possibility of mediastinal nodal disease in patients with potentially 
resectable lung cancers. 
Redo mediastinoscopy
Repeat CM had been reported to be safe but less accurate than ﬁrst time 
CM. The series reported have been relatively small and truly represent 
the experiences of CM experts. One should be very comfortable with 
performing standard CM before attempting a repeat CM. (9) 
Conclusion: Cervical mediastinoscopy remains the gold standard 
technique to evaluate and stage the superior mediastinum by which new 
techniques and imaging are compared and it has been shown to be safe, 
in trained hands. 
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